NovoCure Limited – Material Contracts Watch

from 10-Q 10 pages Termination Agreement by and Between

from 8-K/A 16 pages Chief Executive Officer Employment Agreement

from 10-K 3 pages Non-Employee Director Compensation Program

from 8-K 5 pages Separation and Release Agreement

from 8-K 14 pages 2025 NovoCure Limited Employee Share Purchase Plan

from 10-Q 17 pages Material contract

from 10-K 28 pages NovoCure 2024 Omnibus Incentive Plan Forms of Performance-Based Restricted Share Unit Award Notice

from 10-K 20 pages NovoCure 2024 Omnibus Incentive Plan Forms of Restricted Share Unit Award Notice

from 10-K 17 pages NovoCure 2024 Omnibus Incentive Plan Forms of Share Option Agreement

from 10-K 17 pages Employment Agreement

from 10-K 2 pages NovoCure Limited 2024 Omnibus Incentive Plan Sub-Plan for Switzerland

from 8-K/A 20 pages Amended and Restated Employment Agreement

from 8-K/A 16 pages Chief Executive Officer Employment Agreement

from 8-K 16 pages Chief Financial Officer Employment Agreement

from 8-K 17 pages October 1, 2024 Mr. Wilhelmus Groenhuysen 1150 Queens Rangers Lane West Chester, Pa 19382 USA Dear Wilco

from 8-K 38 pages Definitions

from 10-Q 140 pages Material contract

from 10-K 3 pages NovoCure Limited Non-Employee Director Compensation Program

from 8-K 16 pages The Purposes of This Letter (This “Agreement”) Are to Amend and Restate the Terms and Conditions of Your Prior Agreement (As Defined Below) and to Set Forth and Acknowledge Certain Terms of Your Continued Employment With the NovoCure Group. Your Formal Employment Relationship Will Continue to Be With NovoCure USA LLC, a Delaware Limited Liability Company (The “Company”) and a Wholly Owned Subsidiary of NovoCure Limited, a Jersey (Channel Islands) Corporation (The “Parent”). References Herein to the “Novocure Group” Shall Mean and Refer To, Collectively, the Parent, the Company and Their Respective Direct and Indirect Subsidiaries and Affiliates. Effective January 1, 2024 (The “Effective Date”), This Agreement Will Supersede and Replace in Its Entirety the Employment Letter Agreement Between You and the Company, Dated as of July 25, 2018 (The “Prior Agreement”)

from 8-K 17 pages The Purposes of This Letter (This “Agreement”) Are to Amend and Restate the Terms and Conditions of Your Prior Agreement (As Defined Below) and to Set Forth and Acknowledge Certain Terms of Your Continued Employment With the NovoCure Group. Your Formal Employment Relationship Will Continue to Be With NovoCure USA LLC, a Delaware Limited Liability Company (The “Company”) and a Wholly Owned Subsidiary of NovoCure Limited, a Jersey (Channel Islands) Corporation (The “Parent”). References Herein to the “Novocure Group” Shall Mean and Refer To, Collectively, the Parent, the Company and Their Respective Direct and Indirect Subsidiaries and Affiliates. Effective as of January 1, 2024 (The “Effective Date”), This Agreement Will Supersede and Replace in Its Entirety the Employment Letter Agreement Between You and the Company, Dated as of May 3, 2023 (The “Prior Agreement”)